The Initial Focus Will Be Clinical Studies of the Company's Prana Product Line
DENVER, CO / ACCESSWIRE / January 30, 2017 / United Cannabis Corporation (CNAB) (the "Company" or "United Cannabis") today announced that it, along with its Jamaica-based subsidiary, Cannabis Research & Development ("CRD"), has signed a Letter of Intent (the "LOI") with the Caribbean Institute of Medical Research ("CARIMER") to collaborate on advancing clinical research on medical cannabis.
CARIMER is the Jamaican-based division of MPR Development Group, a full service global Clinical Research and Development Organization ("CRO"). CARIMER also serves as the research arm of several medical facilities and hospitals in the Caribbean and collaborates with health institutions to support health care research projects around the world.
According to the terms of the LOI, studies will be conducted under the supervision of the CARIMER team who will be responsible for coordinating and initiating the research and clinical trials for the Prana P1 thru P5 products. Pre-clinical studies will focus on acute and chronic toxicology, while clinical investigations will begin with pharmacokinetic studies and a dose escalation safety study.
Tony Verzura, Chief Technical Officer of United Cannabis, commented on the announcement, "For several years we have been tracking patient outcomes using Prana P1 - P5 products with the help of our A.C.T. Now Program and have collected a wealth of anecdotal evidence supporting the safety and efficacy of our medications. Our collaboration in Jamaica with CARIMER is the first of many steps to formally test and confirm the benefits of the Prana line for a broad range of diseases in preparation for pharmaceutical markets."
Dr. Lorenzo Gordon, Executive Director of the Caribbean Institute of Medical Research, added, "We have long recognized the medical value of cannabis and United Cannabis' Prana line is one of the most comprehensive treatment programs available. We look forward to working on this important project with them."
Dr. Brent Reynolds, a member of the Company's Advisory Board, went on to say, "The foresight of the Jamaican government and the experience and network of CARIMER provides an ideal setting for United Cannabis to initiate their preclinical and clinical programs. The objective is to rigorously test the safety and efficacy of their cannabinoid-based medicines as they seek to progress their product line down the pharmaceutical drug route."
About the Caribbean Institute of Medical Research
CARIMER is the Jamaican-based division of MPR Development Group, a full service global Clinical Research and Development Organization ("CRO"). CARIMER also serves as the research arm of several medical facilities and hospitals in the Caribbean and collaborates with health institutions to support health care research projects around the world. With locations across the Caribbean, CARIMER provides access to a variety of populations, including patients in remote locations, with nearly all medical indications.
About United Cannabis Corporation
The Company's Prana Bio Medicinal products provide patients a way to mix/match cannabinoids for therapeutic purpose. These products, licensed to regulated marijuana dispensaries, are broken into 5 categories that are available in capsules, sublinguals, and topical delivery methods. The Company uses a patent-pending infusion process utilizing select fatty acids, lipids, and specific combination of cannabis derived terpenes to increase bioavailability.
For further information, please visit www.unitedcannabis.us.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
SOURCE: United Cannabis Corporation